Surgical Treatment of Another Sequalae of COVID-19: Post-COVID CTEPH

Abstract

Background Coronavirus disease 2019 (COVID-19) is still an ongoing entity and every day we face new sequalae of the disease. We hereby present surgical results of patients who are treated for post-COVID chronic thromboembolic pulmonary hypertension.

Methods Data were collected among patients who underwent pulmonary endarterectomy and had a diagnosis of post-COVID chronic thromboembolic pulmonary hypertension. All data were retrospectively reviewed from a prospectively conducted database. Operative mortality was described as death in hospital or within 30 days of surgery.

Results Eleven patients (seven males, four females; median age, 52 [22–63] years) were identified. Pulmonary vascular resistance improved significantly from 572 dyn/s/cm⁻⁵ (240–1,192) to 240 (195–377) dyn/s/cm⁻⁵ (p < 0.005). Significant difference was also detected in median mPAP, as it decreased from 40 mm Hg (24–54) to 24 mm Hg (15–36) following surgery (p < 0.005). Mortality was observed in one patient due to sepsis on the fifth postoperative day. Median time from COVID-19 disease to surgery was 12 months (6–24). Median length of hospital stay of the survivors was 10 days (8–14).

Conclusion In the new era of chronic thromboembolic pulmonary hypertension, hybrid approach including surgery, balloon pulmonary angioplasty, and medical treatment has been recommended. pulmonary endarterectomy is still the only curative treatment when the disease is surgically accessible. We hereby report the first publication of post-COVID chronic thromboembolic pulmonary hypertension patients who were surgically treated. As we see a lot of long-term symptoms and clinical manifestations in patients who had COVID-19, we should always remember chronic thromboembolic pulmonary hypertension in the differential diagnosis.

Keywords

COVID-19 - chronic thromboembolic pulmonary hypertension - post-COVID - long COVID - pulmonary endarterectomy

Publication History

Received: 03 January 2023

Accepted: 14 March 2023

Accepted Manuscript online:
21 March 2023

Article published online:
03 May 2023

• References

• 1 Myoung J. Two years of COVID-19 pandemic: where are we now?. J Microbiol 2022; 60 (03) 235-237
• 2 Martelletti P, Bentivegna E, Spuntarelli V, Luciani M. Long-COVID headache. SN Compr Clin Med 2021; 3 (08) 1704-1706
• 3 Baig AM. Chronic long-COVID syndrome: a protracted COVID-19 illness with neurological dysfunctions. CNS Neurosci Ther 2021; 27 (12) 1433-1436
• 4 Cortés-Telles A, López-Romero S, Figueroa-Hurtado E. et al. Pulmonary function and functional capacity in COVID-19 survivors with persistent dyspnoea. Respir Physiol Neurobiol 2021; 288: 103644
• 5 Raman B, Bluemke DA, Lüscher TF, Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur Heart J 2022; 43 (11) 1157-1172
• 6 Raj SR, Arnold AC, Barboi A. et al; American Autonomic Society. Long-COVID postural tachycardia syndrome: an American Autonomic Society statement. Clin Auton Res 2021; 31 (03) 365-368
• 7 Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol 2021; 12: 698169
• 8 Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond) 2021; 53 (10) 737-754
• 9 Al-Ani F, Chehade S, Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb Res 2020; 192: 152-160
• 10 Spiezia L, Boscolo A, Poletto F. et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost 2020; 120 (06) 998-1000
• 11 Engelen MM, Vandenbriele C, Balthazar T. et al. Venous thromboembolism in patients discharged after COVID-19 hospitalization. Semi Thrombo Hemost 2021; 47 (04) 362-371
• 12 Moores LK, Tritschler T, Brosnahan S. et al. Thromboprophylaxis in patients with COVID-19: a brief update to the CHEST guideline and expert panel report. Chest 2022; 162 (01) 213-225
• 13 Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J 2019; 53 (01) 1
• 14 Guth S, D'Armini AM, Delcroix M. et al. Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry. ERJ Open Res 2021; 7 (03) 3
• 15 Lankeit M, Krieg V, Hobohm L. et al. Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2017; 37 (02) 250-258
• 16 Yıldızeli B, Taş S, Yanartaş M. et al. Pulmonary endarterectomy for chronic thrombo-embolic pulmonary hypertension: an institutional experience. Eur J Cardiothorac Surg 2013; 44 (03) e219-e227 , discussion e227
• 17 Adeloye D, Elneima O, Daines L. et al; International COVID-19 Airways Diseases Group. The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease. Lancet Respir Med 2021; 9 (12) 1467-1478
• 18 Yong SJ, Liu S. Proposed subtypes of post-COVID-19 syndrome (or long-COVID) and their respective potential therapies. Rev Med Virol 2022; 32 (04) e2315
• 19 Garg M, Maralakunte M, Garg S. et al. The conundrum of ‘long-COVID-19’: a narrative review. Int J Gen Med 2021; 14: 2491-2506
• 20 Miró Ò, Jiménez S, Mebazaa A. et al; Spanish Investigators on Emergency Situations TeAm (SIESTA) network. Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome. Eur Heart J 2021; 42 (33) 3127-3142
• 21 Martinez Licha CR, McCurdy CM, Maldonado SM, Lee LS. Current management of acute pulmonary embolism. Ann Thorac Cardiovasc Surg 2020; 26 (02) 65-71
• 22 Heit JA, Cohen AT, Anderson JR FA. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood 2005; 106 (11) 910
• 23 Cohen AT, Agnelli G, Anderson FA. et al; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98 (04) 756-764
• 24 Jiménez D, García-Sanchez A, Rali P. et al Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. Chest 2021; 159 (03) 1182-1196
• 25 Poissy J, Goutay J, Caplan M. et al; Lille ICU Haemostasis COVID-19 Group. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation 2020; 142 (02) 184-186
• 26 Poor HD. Pulmonary thrombosis and thromboembolism in COVID-19. Chest 2021; 160 (04) 1471-1480
• 27 Jayarangaiah A, Kariyanna PT, Chen X, Jayarangaiah A, Kumar A. COVID-19-associated coagulopathy: an exacerbated immunothrombosis response. Clin Appl Thromb Hemost 2020; 26: 1076029620943293
• 28 Kim NH, Delcroix M, Jenkins DP. et al. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2013; 62 (25, Suppl): D92-D99
• 29 Sharma S, Lang IM. Current understanding of the pathophysiology of chronic thromboembolic pulmonary hypertension. Thromb Res 2018; 164: 136-144
• 30 Cueto-Robledo G, Roldan-Valadez E, Graniel-Palafox LE. et al. Chronic thromboembolic pulmonary hypertension (CTEPH): a review of another sequel of severe post-Covid-19 pneumonia. Curr Probl Cardiol 2023; 48 (08) 101187